Lepu Scientech's MemoCarna Oxide Film Single‑Rivet PFO Occluder Approved for Market Launch by NMPA – Novel Design Targets Residual Shunts in Patent Foramen Ovale Closure
CompanyMedical Device

Lepu Scientech’s MemoCarna Oxide Film Single‑Rivet PFO Occluder Approved for Market Launch by NMPA – Novel Design Targets Residual Shunts in Patent Foramen Ovale Closure

Lepu Scientech Medical Technology (HKG: 2291) announced that its MemoCarna oxide film single‑rivet patent foramen ovale (PFO) occluder, independently developed by the company, has been approved for market launch by…

CompanyDrug

Luzhu Biotech’s Self‑Developed Recombinant RSV Vaccine Candidate Approved for Clinical Trials by NMPA – Pre‑F Protein Antigen Advances Toward Prevention of RSV Lower Respiratory Tract Disease

BrightGene's BGM0504 Approved for Clinical Trials in China – In‑House Dual GLP‑1/GIP Receptor Agonist Advances Toward Adult Type 2 Diabetes
CompanyDrug

BrightGene’s BGM0504 Approved for Clinical Trials in China – In‑House Dual GLP‑1/GIP Receptor Agonist Advances Toward Adult Type 2 Diabetes

Beijing Balance Medical's Transcatheter Pulmonary Valve System Wins NMPA Approval – Third Innovative‑Device Clearance Redefines TPVR with Transthoracic Remodeling Approach
CompanyMedical Device

Beijing Balance Medical’s Transcatheter Pulmonary Valve System Wins NMPA Approval – Third Innovative‑Device Clearance Redefines TPVR with Transthoracic Remodeling Approach

Chipscreen Biosciences' CS43158 Wins NMPA Clinical Trial Approval – Multi‑Target Kinase Inhibitor Aims to Overcome FLT3 Resistance in Acute Myeloid Leukemia
CompanyDrug

Chipscreen Biosciences’ CS43158 Wins NMPA Clinical Trial Approval – Multi‑Target Kinase Inhibitor Aims to Overcome FLT3 Resistance in Acute Myeloid Leukemia

- Advertisement -
Ad image
Biokin Scores Triple NMPA Breakthrough Therapy Designation – BL-M07D1, BL-M05D1, and Iza‑Bren Recognized Across Biliary Tract and Gastric Cancers
CompanyDrug

Biokin Scores Triple NMPA Breakthrough Therapy Designation – BL-M07D1, BL-M05D1, and Iza‑Bren Recognized Across Biliary Tract and Gastric Cancers

Biokin's BL-M12D1 Wins NMPA Clinical Trial Approval – ADC Candidate to Be Evaluated as Monotherapy in Relapsed or Refractory Hematologic Malignancies
CompanyDrug

Biokin’s BL-M12D1 Wins NMPA Clinical Trial Approval – ADC Candidate to Be Evaluated as Monotherapy in Relapsed or Refractory Hematologic Malignancies

Haisco's HSK42360-Na Granted NMPA Breakthrough Therapy Designation – BRAF Paradoxical Breaker Targets High‑Grade Glioma with BRAF V600 Mutation
CompanyDrug

Haisco’s HSK42360-Na Granted NMPA Breakthrough Therapy Designation – BRAF Paradoxical Breaker Targets High‑Grade Glioma with BRAF V600 Mutation

Neurorevix Completes Tens of Millions RMB Angel Round Led by HSG – BCI and Neuromodulation Pioneer Advances "Closed‑Loop Nerve Bundle Modulation" Platform
CompanyDeals

Neurorevix Completes Tens of Millions RMB Angel Round Led by HSG – BCI and Neuromodulation Pioneer Advances “Closed‑Loop Nerve Bundle Modulation” Platform

Boehringer Ingelheim and WHO Foundation Launch Three‑Year, USD 5 Million Collaboration to Tackle Obesity in Resource‑Limited Settings
CompanyDeals

Boehringer Ingelheim and WHO Foundation Launch Three‑Year, USD 5 Million Collaboration to Tackle Obesity in Resource‑Limited Settings

Three Oncology Assets Join CDE Pilot Programs – ICP‑B794 and Aponermin Enter "Care Program – Extension" While GH56 Advances Pediatric Development
Policy / Regulatory

Three Oncology Assets Join CDE Pilot Programs – ICP‑B794 and Aponermin Enter “Care Program – Extension” While GH56 Advances Pediatric Development

Leads Biolabs' LBL-024 Granted Orphan Drug Designation by Japan's MHLW – Anti‑PD‑L1/4‑1BB Bispecific Antibody Advances in Extrapulmonary Neuroendocrine Carcinoma
CompanyDrug

Leads Biolabs’ LBL-024 Granted Orphan Drug Designation by Japan’s MHLW – Anti‑PD‑L1/4‑1BB Bispecific Antibody Advances in Extrapulmonary Neuroendocrine Carcinoma

Evive Biotech Doses First Participant in Phase II Study of F-652 for Acute GVHD – Yifan Pharmaceutical's First‑in‑Class IL-22 Fusion Protein Advances Post‑HSCT Treatment
CompanyDrug

Evive Biotech Doses First Participant in Phase II Study of F-652 for Acute GVHD – Yifan Pharmaceutical’s First‑in‑Class IL-22 Fusion Protein Advances Post‑HSCT Treatment

Synphatec Completes Over USD 50 Million Series A to Advance CNS Pipeline – Rapid‑Acting Antidepressant SP-101 and Alzheimer's Gene Therapy SP-201 Enter Next Development Phase
CompanyDeals

Synphatec Completes Over USD 50 Million Series A to Advance CNS Pipeline – Rapid‑Acting Antidepressant SP-101 and Alzheimer’s Gene Therapy SP-201 Enter Next Development Phase

Earendil Labs Strikes Bispecific Antibody Deal with Genentech – $55 Million Upfront, Total Value Tops $1.5 Billion in Oncology
CompanyDeals

Earendil Labs Strikes Bispecific Antibody Deal with Genentech – $55 Million Upfront, Total Value Tops $1.5 Billion in Oncology

Company

Tigermed Posts 14% Revenue Growth in 2026 Interim Results – China’s No.1 Clinical CRO Sees Bookings Rebound While Fair‑Value Losses Swing Reported Profit Negative

Rainmed Medical Reports 41% Revenue Growth in 2026 Interim Results – caFFR Consumables Drive Gross Margin to 63.2% as Losses Narrow 31%
Company

Rainmed Medical Reports 41% Revenue Growth in 2026 Interim Results – caFFR Consumables Drive Gross Margin to 63.2% as Losses Narrow 31%

Show More